|

Prostatic Size Reduction Following of Leuprorelin Acetate

RECRUITINGSponsored by Consorci Sanitari de Terrassa
Actively Recruiting
SponsorConsorci Sanitari de Terrassa
Started2024-02-02
Est. completion2024-12-15
Eligibility
Age18 Years – 95 Years
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06184464

Summary

To determine the possible reduction in prostate size following the administration of Leuprelin prior to the application of radiotherapy.

Eligibility

Age: 18 Years – 95 YearsSex: MALEHealthy volunteers accepted
Inclusion Criteria:

Man with Prostate positive biopsy. Able to Ssgned informed consent form. Need of hormonal treatment before start of radiotherapy

Exclusion Criteria:

Patients With prostate size of less than 20 cc at diagnosis. Patients With Positive lymph nodes or metastatic prostate cancer disease on imaging studies.

Patients with Previous pelvic radiation therapy.

Conditions3

CancerProstate AdenocarcinomaProstate Cancer (Adenocarcinoma)

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.